MARKET

BCRX

BCRX

Biocryst Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.10
+0.07
+0.78%
After Hours: 9.15 +0.05 +0.55% 19:08 05/20 EDT
OPEN
9.11
PREV CLOSE
9.03
HIGH
9.20
LOW
8.67
VOLUME
3.20M
TURNOVER
--
52 WEEK HIGH
19.99
52 WEEK LOW
7.61
MARKET CAP
1.69B
P/E (TTM)
-8.5055
1D
5D
1M
3M
1Y
5Y
9 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Benzinga · 4d ago
--Oppenheimer Adjusts BioCryst Pharmaceuticals Price Target to $13 From $16, Maintains Outperform Rating
MT Newswires · 05/12 10:58
FDA makes partial clinical hold official for Durham firm's drug candidate
The move by the FDA comes after the company voluntarily paused enrollment in multiple clinical trials over concerns about potential kidney dysfunction in patients.
American City Business Journals · 05/06 20:11
BioCryst to Present at Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., May 06, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the following conferences: The Bank of America Securities 2022 Healthcare Conference in Las Vegas,...
GlobeNewswire · 05/06 11:00
--RBC Cuts Price Target on BioCryst Pharmaceuticals to $13 From $14, Maintains Sector Perform-Speculative Risk Rating
MT Newswires · 05/06 08:20
BioCryst's Voluntary Pause Of Rare Blood Disorder Trial Turns Into FDA Clinical Hold
Benzinga · 05/05 19:33
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/05 12:43
BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Lags Revenue Estimates
BioCryst (BCRX) delivered earnings and revenue surprises of -2.56% and 1.33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/05 12:25
More
No Data
Learn about the latest financial forecast of BCRX. Analyze the recent business situations of Biocryst Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

7.69%Strong Buy
53.85%Buy
38.46%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average BCRX stock price target is 17.45 with a high estimate of 30.00 and a low estimate of 11.00.
High30.00
Average17.45
Low11.00
Current 9.10
EPS
Actual
Estimate
-0.32-0.24-0.16-0.08
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 300
Institutional Holdings: 139.07M
% Owned: 74.93%
Shares Outstanding: 185.58M
TypeInstitutionsShares
Increased
66
16.17M
New
50
10.57M
Decreased
66
14.35M
Sold Out
21
2.16M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.65%
Pharmaceuticals & Medical Research
+1.64%
Key Executives
Non-Executive Chairman/Independent Director
Robert Ingram
Chief Executive Officer/President/Director
Jon Stonehouse
Chief Financial Officer
Anthony Doyle
Other/IR Contact Officer
John Bluth
Other
Yarlagadda Babu
Other
Charles Gayer
Other
Jinky Rosselli
Other
William Sheridan
Other
Helen Thackray
Secretary
Alane Barnes
Independent Director
George Abercrombie
Independent Director
Stephen Aselage
Independent Director
Steven Galson
Independent Director
Theresa Heggie
Independent Director
Nancy Hutson
Independent Director
Kenneth Lee
Independent Director
Alan Levin
Independent Director
Amy Mckee
Independent Director
Vincent Milano
Independent Director
A. Machelle Sanders
No Data
No Data
About BCRX
BioCryst Pharmaceuticals, Inc. (BioCryst) is a commercial-stage biotechnology company that discovers small-molecule medicines. The Company focus on oral treatments for rare diseases in which unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. ORLADEYO (berotralstat) is an oral, once-daily therapy that is approved in the United States, the European Union, Japan, and the United Kingdom for the prevention of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years and older. BioCryst has several ongoing development programs, including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an activin receptor-like kinase-2 (ALK-2) inhibitor for the treatment of fibrodysplasia ossificans progressiva, and Galidesivir, an antiviral drug for Marburg virus disease and Yellow Fever. RAPIVAB (peramivir injection) is a viral neuraminidase inhibitor for the treatment of influenza.

Webull offers kinds of BioCryst Pharmaceuticals, Inc. stock information, including NASDAQ:BCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BCRX stock methods without spending real money on the virtual paper trading platform.